Indo US Bio-Tech Limited

Indo US Bio-Tech Limited

INDOUS.BO
Indo US Bio-Tech LimitedIN flagBombay Stock Exchange
87.28
INR
-2.11
- -
1.75BMarket Cap
Indo US Bio-Tech Limited
INDOUS.BO
(Bombay Stock Exchange)

Recent

price

87.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
10.25
10.17
13.44
13.08
16.83
28.66
25.08
27.3
27.54
40.9
64.02
36.32
51.77
55.04
55.01
Revenue per Share
0.21
0.18
0.34
0.25
0.27
1.41
1.48
1.74
3.36
4.14
7.51
4.11
8.11
6.54
6.54
Basic EPS, GAAP
-0.67
0.18
-0.02
-1.85
-0.07
-1.3
-3.17
-0.85
-1.23
-1.03
-1.34
-0.19
0.28
-7.47
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.12
- -
- -
0.25
- -
- -
Dividend per Share
0.82
0.82
1.02
1.02
2.4
4.81
6
8.38
11.75
19.53
33.57
20.25
28.11
9.99
9.99
Book Value per Share
1.26
1.44
1.99
2.23
2.4
4.81
9.87
11.29
14.66
31.46
56.5
31.29
39.14
46.12
46.09
Tangible Book Value per Share
15
15
15
15
15
10
14
15
15
12
10
20
20
20
20
Basic Weighted Avg Shares
149
148
196
190
245
294
353
398
401
501
617
728
1,038
1,104
1,104
Sales/Revenue/Turnover
2.99
1.92
2.84
1.95
4.72
8.71
9.07
9.48
12.75
13.31
13.91
14.23
17.18
14.59
14.59
Operating Margin (%)
1
1
1
1
1
2
2
2
3
4
8
8
11
9
9
Depreciation Expense
3
3
5
4
4
14
21
25
49
51
72
82
163
131
131
Net Income, GAAP
- -
- -
- -
- -
24.08
28.98
25.7
11.49
- -
4.67
1.98
6.29
1.59
5.73
5.73
Effective Tax Rate (%)
2.01
1.75
2.53
1.89
1.62
4.92
5.91
6.37
12.22
10.11
11.73
11.31
15.67
11.88
11.88
Profit Margin (%)
10
8
18
18
23
48
125
152
200
346
476
542
704
812
812
Working Capital
- -
- -
5
2
3
14
7
8
35
37
17
28
29
10
10
LT Debt
18
21
29
33
35
49
139
164
213
385
545
627
785
925
925
Total Equity
- -
- -
- -
- -
10.89
18.5
15.1
14.8
- -
15.65
14.86
13.99
21.15
13.74
13.74
Return on Invested Capital (%)
- -
- -
- -
- -
12.08
19.49
17.91
18.23
- -
18.82
20.67
19.33
28.11
23.75
23.75
Return on Capital (%)
- -
21.84
37.04
24.17
15.9
34.36
31.17
24.53
33.43
24.69
25.73
22.58
33.55
34.34
34.34
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
262
- -
361
LT Borrowings
14
- -
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
- -
20
Market Capitalization
2,726
2,453
1,966

Working Capital

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,068
- -
1,207
Cash, Cash Equivalents & STI
6
- -
69
Accounts Receivable, Net
334
- -
138
Inventories
609
- -
1,000
Total Current Liabilities
291
- -
395
Payables & Accruals
- -
- -
- -
ST Debt
262
- -
361
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
45.83%
36.01%
17.85%
Free Cash Flow
-180.2%
-626.09%
-2,790.13%
Net Income, GAAP
57.29%
27.65%
-19.33%
Sales/Revenue/Turnover
19.72%
23%
6.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
191
158
221
370
728
2025
247
222
236
228
1,038
2026
308
308
228
260
1,104

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.18
0.83
1.84
- -
4.11
2025
1.58
2.16
2.52
1.49
8.11
2026
2.35
1.72
1.49
0.98
6.54

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.25
2026
- -
- -
- -
- -
- -
Business
Indo US Bio-Tech Limited engages in crop research and development through breeding, production, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of agricultural seeds; offers vegetable seeds including tomato, okra, bottle gourd, brinjal, carrot, cluster bean, and bitter gourd; cotton seeds; oil seeds; spices seeds; pulses seeds; and cereals seeds; provides seed testing, soil testing, and water testing services through its in-house laboratory. The company operates primarily in India with a nationwide marketing network of over 5,500 dealers and distributors serving more than 100,000 farmers, focusing on climate-resilient varieties tolerant to heat, cold, humidity, and diseases; its DSIR-recognized R&D center in Modasa, Gujarat, integrates biotechnology and genetic engineering with conventional breeding. Founded in 2004 and headquartered in Ahmedabad, Gujarat, the company, originally incorporated as Pollucid Bio-Tech Private Limited, maintains ISO 9001-2008 certification and membership in the National Seed Association of India. Recent developments include strong financial growth with compounded sales growth of 18% over 10 years and 21% over 5 years, robust profit expansion at 45% CAGR over 5 years, and participation in the APSA Seed Congress 2025 in Mumbai from November 17-20; it approved unaudited financial results for the half-year ended September 30, 2025, reflecting ongoing operational momentum amid improved debtor days and high ROCE of 21%.